266 related articles for article (PubMed ID: 27568223)
1. Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection.
Cornelius C; Schöneweis K; Georgi F; Weber M; Niederberger V; Zieglmayer P; Niespodziana K; Trauner M; Hofer H; Urban S; Valenta R
EBioMedicine; 2016 Sep; 11():58-67. PubMed ID: 27568223
[TBL] [Abstract][Full Text] [Related]
2. Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32.
Tulaeva I; Cornelius C; Zieglmayer P; Zieglmayer R; Schmutz R; Lemell P; Weber M; Focke-Tejkl M; Karaulov A; Henning R; Valenta R
EBioMedicine; 2020 Sep; 59():102953. PubMed ID: 32855110
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Focke-Tejkl M; Weber M; Niespodziana K; Neubauer A; Huber H; Henning R; Stegfellner G; Maderegger B; Hauer M; Stolz F; Niederberger V; Marth K; Eckl-Dorna J; Weiss R; Thalhamer J; Blatt K; Valent P; Valenta R
J Allergy Clin Immunol; 2015 May; 135(5):1207-7.e1-11. PubMed ID: 25441634
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
[TBL] [Abstract][Full Text] [Related]
5. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG
Eckl-Dorna J; Weber M; Stanek V; Linhart B; Ristl R; Waltl EE; Villazala-Merino S; Hummel A; Focke-Tejkl M; Froeschel R; Neubauer A; Henning R; Perkmann T; Valenta R; Niederberger V
EBioMedicine; 2019 Dec; 50():421-432. PubMed ID: 31786130
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
[TBL] [Abstract][Full Text] [Related]
7. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
[TBL] [Abstract][Full Text] [Related]
8. Oral administration of a chimeric Hepatitis B Virus S/preS1 antigen produced in lettuce triggers infection neutralizing antibodies in mice.
Dobrica MO; Lazar C; Paruch L; van Eerde A; Clarke JL; Tucureanu C; Caras I; Ciulean S; Onu A; Tofan V; Branzan A; Urban S; Stavaru C; Branza-Nichita N
Vaccine; 2018 Sep; 36(38):5789-5795. PubMed ID: 30082163
[TBL] [Abstract][Full Text] [Related]
9. A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice.
Cai X; Zheng W; Pan S; Zhang S; Xie Y; Guo H; Wang G; Li Z; Luo M
Antiviral Res; 2018 Jan; 149():48-57. PubMed ID: 29129705
[TBL] [Abstract][Full Text] [Related]
10. Development of a more efficient hepatitis B virus vaccine by targeting hepatitis B virus preS to dendritic cells.
Jing M; Wang J; Zhu S; Ao F; Wang L; Han T; Yue X; Zhu Y; Ye L; Liu S
Vaccine; 2016 Jan; 34(4):516-522. PubMed ID: 26686999
[TBL] [Abstract][Full Text] [Related]
11. "Dual use": The anti-allergy vaccine BM32 and its HBV carrier protein.
Gerlich WH
EBioMedicine; 2020 Oct; 60():102998. PubMed ID: 32977164
[No Abstract] [Full Text] [Related]
12. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.
Chow YH; Huang WL; Chi WK; Chu YD; Tao MH
J Virol; 1997 Jan; 71(1):169-78. PubMed ID: 8985336
[TBL] [Abstract][Full Text] [Related]
13. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
[TBL] [Abstract][Full Text] [Related]
14. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus.
Yang HJ; Chen M; Cheng T; He SZ; Li SW; Guan BQ; Zhu ZH; Gu Y; Zhang J; Xia NS
World J Gastroenterol; 2005 Jan; 11(4):492-7. PubMed ID: 15641132
[TBL] [Abstract][Full Text] [Related]
15. Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy.
Khaitov M; Shilovskiy I; Valenta R; Weber M; Korneev A; Tulaeva I; Gattinger P; van Hage M; Hofer G; Konradsen JR; Keller W; Akinfenwa O; Poroshina A; Ilina N; Fedenko E; Elisyutina O; Litovkina A; Smolnikov E; Nikonova A; Rybalkin S; Aldobaev V; Smirnov V; Shershakova N; Petukhova O; Kudlay D; Shatilov A; Timofeeva A; Campana R; Udin S; Skvortsova V
Allergy; 2024 Apr; 79(4):1001-1017. PubMed ID: 37855043
[TBL] [Abstract][Full Text] [Related]
16. PreS antigen expression and anti-preS response in hepatitis B virus infections: relationship to serum HBV-DNA, intrahepatic HBcAg, liver damage and specific T-cell response.
Petit MA; Capel F; Zoulim F; Dubanchet S; Chemin I; Penna A; Ferrari C; Trépo C
Arch Virol Suppl; 1992; 4():105-12. PubMed ID: 1280500
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing.
Neurath AR; Kent SB; Parker K; Prince AM; Strick N; Brotman B; Sproul P
Vaccine; 1986 Mar; 4(1):35-7. PubMed ID: 2421497
[TBL] [Abstract][Full Text] [Related]
18. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.
Bremer CM; Sominskaya I; Skrastina D; Pumpens P; El Wahed AA; Beutling U; Frank R; Fritz HJ; Hunsmann G; Gerlich WH; Glebe D
J Hepatol; 2011 Jul; 55(1):29-37. PubMed ID: 21145866
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the epitope and neutralizing capacity of human monoclonal antibodies induced by hepatitis B vaccine.
Tajiri K; Ozawa T; Jin A; Tokimitsu Y; Minemura M; Kishi H; Sugiyama T; Muraguchi A
Antiviral Res; 2010 Jul; 87(1):40-9. PubMed ID: 20412816
[TBL] [Abstract][Full Text] [Related]
20. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.
Niespodziana K; Focke-Tejkl M; Linhart B; Civaj V; Blatt K; Valent P; van Hage M; Grönlund H; Valenta R
J Allergy Clin Immunol; 2011 Jun; 127(6):1562-70.e6. PubMed ID: 21411130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
